Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 9 January 2026 - 13 January 2026

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

Nvidia stock in premarket: H200 China payment clarification, Lilly AI lab and TSMC earnings in focus

New York, Jan 13, 2026, 08:38 EST — Premarket Nvidia shares showed little movement in premarket trading Tuesday following the company’s announcement that customers won’t need to pay upfront for its H200 chip, a data-center GPU designed for AI model training and deployment. The stock inched up roughly 0.03% to $184.94. (Reuters) The remark comes amid a market viewing China as a critical factor for Nvidia—not a collapse scenario, but a region where red tape and regulations can delay shipments that would otherwise boost revenue. With Nvidia’s stock often driven by the next quarter’s supply and demand, even minor hiccups
13 January 2026
·······
Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

Eli Lilly stock moves after-hours on fast-track weight-loss pill talk and Nvidia AI lab deal

New York, January 12, 2026, 5:46 PM EST — After-hours Eli Lilly stock rose about 1.6% in after-hours trading on Monday, last at $1,081, after a top research executive said the drugmaker expects to have enough supply to launch its experimental weight-loss pill orforglipron in “many, many countries” as it nears a U.S. regulatory decision. (Reuters) The comments matter now because investors have been treating the obesity drug market as the main driver of Lilly’s revenue momentum — and pills could pull in patients who avoid injections or lack insurance coverage. Pills also shift the fight with Novo Nordisk from
13 January 2026
·····
Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

Nvidia stock barely moves after hours as $1 billion Eli Lilly AI lab plan lands

New York, January 12, 2026, 16:30 EST — Trading after-hours. Nvidia shares held steady in after-hours trading Monday following the announcement that the chipmaker and Eli Lilly plan to launch a joint AI research lab focused on accelerating drug discovery. This deal is significant as Nvidia looks to embed its chips and software more firmly into sectors beyond the typical cloud giants. Healthcare stands out as one of the rare fields where fresh AI workloads can emerge without waiting on the next tech spending wave. Traders, however, are focused mainly on one factor: the strength and consistency of demand for
12 January 2026
······
Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings

Nvidia stock gains on Eli Lilly $1 billion AI lab plan as traders eye TSMC, earnings

New York, January 12, 2026, 12:53 EST — Regular session underway. Nvidia shares climbed roughly 0.8% Monday following news the chipmaker and Eli Lilly plan to pour up to $1 billion into an AI lab designed to accelerate drug discovery over the next five years. Nvidia closed at $186.37, while Lilly edged up about 0.2% to $1,066.14. (Reuters) Wall Street is leaning back into the AI trade that powered last year’s rally, even as investors prepare for Tuesday’s U.S. inflation report and the kick-off of major bank earnings. The S&P 500 hovered near record levels with little movement, while the
12 January 2026
·····
Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

Nvidia stock wobbles after $1B Eli Lilly AI lab plan as CPI and TSMC loom

NEW YORK, Jan 12, 2026, 10:43 a.m. ET — Regular session Nvidia (NVDA.O), the world’s most valuable listed company, and Eli Lilly (LLY.N) said on Monday they will spend $1 billion over five years on a joint research lab in the San Francisco Bay Area, betting Nvidia’s next Vera Rubin AI chips can speed drug discovery. Nvidia shares were down 0.2% at $184.42 by 10:30 a.m. ET. (Reuters) The move gives Nvidia another lane to sell chips and software as investors debate how long the AI spending surge by Big Tech can stay at full tilt. For Lilly, it is
12 January 2026
·······
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

New York, Jan 12, 2026, 10:58 EST — Regular session Eli Lilly’s stock climbed in early trading Monday following the announcement that the drugmaker and Nvidia plan to invest roughly $1 billion over five years in a joint research lab focused on accelerating drug discovery. The news comes as executives and investors gather at the J.P. Morgan Healthcare Conference in San Francisco, where buzz around drug pipelines can quickly shift valuations in a sector still relying on a handful of blockbuster drugs. AI is increasingly woven into the narrative, particularly for firms eager to prove they can go beyond their
12 January 2026
·······
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

New York, Jan 11, 2026, 10:13 EST — Market closed Eli Lilly and Company shares dropped 1.99% on Friday, closing at $1,063.56. The stock heads into Monday’s session under pressure after a volatile week for major pharmaceutical firms. Investors are closely eyeing signs of a pricing battle in the obesity-drug sector after Amazon Pharmacy announced it now stocks Novo Nordisk’s Wegovy pill, available both through insurance and a cash-pay plan starting at $149 a month. Amazon added that eligible customers with commercial insurance might pay as little as $25 for a single month’s supply. The timing is key as the
11 January 2026
·········
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

NEW YORK, Jan 10, 2026, 13:31 EST — Market closed U.S. healthcare stocks ended the week weaker, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.5% to $157.31 on Friday. This ETF, often seen as a benchmark for major U.S. healthcare companies, has shown volatility as investors brace for a packed schedule of sector developments. The industry’s annual dealmaking and investor tour is about to ramp up, and healthcare’s stakes are high. Traders are debating if this year will see a surge in biotech and medtech acquisitions, and whether major drugmakers move from discussion to actual deals. The
10 January 2026
······
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

NEW YORK, January 10, 2026, 10:08 EST — Market closed Eli Lilly & Co shares fell 2% on Friday to $1,063.56, underperforming a stronger broader market and extending a two-day slide. The stock is now 6.21% below its 52-week high of $1,133.95 set on Thursday, while trading volume ran below its recent average. The pullback lands as investors re-price big pharma growth names ahead of a busy stretch of healthcare headlines, from deal chatter to new drug readouts. Bankers and lawyers have been heading to San Francisco for next week’s J.P. Morgan Healthcare Conference, betting the tone on mergers could
10 January 2026
·····
Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens

NEW YORK, Jan 10, 2026, 08:12 (EST) Schrödinger announced it will integrate Eli Lilly’s TuneLab, an AI-driven drug discovery platform, into its LiveDesign software. This move offers biotech teams direct access to Lilly’s predictive models. “LiveDesign will be a priority platform partner for TuneLab workflows,” said Pat Lorton, Schrödinger’s software chief. (FinancialContent) The deal comes as drugmakers ramp up AI efforts to speed candidate identification and detect safety concerns earlier—a push gaining momentum amid regulatory pressure to reduce animal testing. LiveDesign aids chemists in designing compounds and forecasting properties like absorption and distribution, key to understanding how drugs enter and
10 January 2026
····
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

New York, Jan 9, 2026, 17:30 EST — After-hours Eli Lilly and Co shares fell nearly 2% on Friday, closing at $1,063.56, after swinging between about $1,063 and $1,104 in the session. The stock was little changed after hours. The pullback comes as the drugmaker’s stock cools off from a fresh 52-week high set on Thursday, with traders quick to lock in gains after a fast run. The broader market rose on the day, but Lilly logged a second straight decline and ended the session about 6% below that recent peak. (MarketWatch) The latest company catalyst landed late Thursday, when
9 January 2026
···
Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

New York, Jan 9, 2026, 11:27 EST — Regular trading Eli Lilly and Company (LLY) shares were down about 0.4% at $1,081 in morning trade on Friday. The drugmaker said this week it will buy autoimmune developer Ventyx Biosciences for $1.2 billion in cash, bringing oral candidates for inflammatory bowel disease into its pipeline. The $14-a-share offer is slated to close in the first half of 2026, and Cantor Fitzgerald analyst Carter Gould described the price as “borderline immaterial” for Lilly. (Reuters) Lilly’s stock has been trading on the next act as much as the drugs it’s selling today. With
9 January 2026
·····
1 … 4 5 6 7 8 … 13

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Go toTop